Feb 27 (Reuters) - Aveo Pharmaceuticals Inc :
* Aveo and Astellas announce FDA advisory committee to review tivozanib for the treatment of advanced renal cell carcinoma
* Says FDA review of tivozanib NDA is expected to be complete by July 28, 2013
* U.S. FDA's oncologic drugs advisory committee will review NDA for tivozanib on may 2, 2013
* Source text * Further company coverage
((Bangalore Newsroom; +1 646 223 8780))
0 comments:
Post a Comment